Advertisement

Late Resistance to Captopril

  • Robert C. Tarazi
  • Emmanuel L. Bravo
  • Fetnat M. Fouad

Abstract

The effectiveness of captopril in the treatment of hypertension has been widely demonstrated by many investigators both in the United States and abroad (1–4). Effective blood pressure control was obtained in both essential and renal hypertensions, both moderate and severe and whether associated with high, normal, or low plasma-renin activity (2, 3). In that respect, comparison of early and late responses to converting enzyme inhibition has demonstrated both similarities and contrasts between the two as regards the correlates of blood pressure control (5, 6). Alterations with time in the pattern of responses to captopril would have important implications for understanding the mechanism(s) of its effectiveness and for its use in daily practice.

Keywords

Blood Pressure Control Blood Pressure Response Resistant Hypertension Total Peripheral Resistance Late Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN (1978) Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14225, captopril) in hypertensive patients. Prog Cardiovasc Dis 21: 195–206PubMedCrossRefGoogle Scholar
  2. 2.
    Bravo EL, Tarazi RC (1979) Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1 (1): 39–46PubMedGoogle Scholar
  3. 3.
    Gavras H, Brunner HR, Turini G A, Kershaw SG, Tifft CP, Cuttlelod S, Gavras I, Vukovich RA, McKinstry DN (1978) Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14,225 in man. N Engl J Med 298: 991–995PubMedCrossRefGoogle Scholar
  4. 4.
    Fagard R, Amery A, Reybrouck T, Lijnen P, Billet L (1980) Acute and chronic systemic and pulmonary hemodynamic effects of captopril in hypertensive patients. Am J Cardiol (In press)Google Scholar
  5. 5.
    Fouad FM, Ceimo JMK, Tarazi RC, Bravo EL(1980) Contrasts and similarities of acute hemodynamic responses to specific antagonism of angiotensin II ([Sar1, Thr8]AII) and to inhibition of converting enzyme (captopril). Circulation 61: 163–169Google Scholar
  6. 6.
    Fouad FM, Tarazi RC, Bravo EL, Saragoca M (1981) Similarities and contrasts between angiotensin II antagonists and the acute and long term effects of captopril. In: Program: Sixth scientific session of the International Society of Hypertension, Goteborg, Sweden, June 11–13, 1979, p 134 (Abst)Google Scholar
  7. 7.
    Tarazi RC (1978) Therapy for multifactorial hypertension. Ann Intern Med 88 (5): 705–706PubMedGoogle Scholar
  8. 8.
    Tarazi RC, Fouad FM, Bravo EL (1981) Total peripheral resistance and beta-adrenergic blockade. (This volume)Google Scholar
  9. 9.
    Dustan HP, Tarazi RC, Bravo EL (1975) Hemodynamic adjustments during long-term antihypertensive therapy. In: Milliez P, Safar M (eds) Recent advances in hypertension. Laboratoires Boehringer Ingelheim, France, Vol 2, pp 247–258Google Scholar
  10. 10.
    Tarazi RC, Bravo EL, Fouad FM, Omvik P, Cody RJ Jr (1981) Hemodynamic and volume changes associated with captopril. Hypertension (To be published)Google Scholar
  11. 11.
    Gilford RW Jr, Tarazi RC (1978) Resistant hypertension: Diagnosis and management. Ann Intern Med 88: 661–665Google Scholar
  12. 12.
    Sullivan JM, Ginsburg BA, Ratts TE, Johnson JG, Barton BR, Kraus DH, McKinstry DN, Muirhead EE (1979) Hemodynamic and antihypertensive ef-fects of captopril, an orally active angiotensin converting enzyme inhibitor. Hypertension 1 (4): 397–401PubMedGoogle Scholar
  13. 13.
    Sen S, Tarazi RC, Bumpus FM (1980) Effect of converting enzyme inhibitor (SQ 14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 2 (2): 169–176PubMedGoogle Scholar
  14. 14.
    Koike H, Ito K, Miyamoto M, Nishino H (1980) Effects of long-term blockade of angiotensin coverting enzyme with captopril (SQ 14,225) on hemodynamics and circulating blood volume in SHR. Hypertension 2 (3): 299–303PubMedGoogle Scholar
  15. 15.
    Tarazi RC, Fouad FM, Ceimo JMK, Bravo EL (1979) Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure. Am J Cardiol 44: 1013–1018PubMedCrossRefGoogle Scholar
  16. 16.
    Tarazi RC, Dustan HP, Bravo EL (1979) Hemodynamic effects of propranolol in hypertension. Post-grad Med J 52 (Suppl IV ) 52: 92–100Google Scholar
  17. 17.
    Tarazi RC, Dustan HP, Bravo EL (1972) The importance of plasma volume in the treatment of hypertension. In: Schweizer W (ed) Beta-blockers—Present status and future prospects. Hans Huber, Bern Switzerland, pp 102–119Google Scholar
  18. 18.
    Smith AJ (1965) Clinical features of fluid retention complicating treatment with guanethidine. Circulation 31: 485–489PubMedGoogle Scholar
  19. 19.
    Hansen J (1968) Alpha-methyl-dopa (Aldomet) in the treatment of hypertension: effect on blood volume, exchangeable sodium, body weight and blood pressure. Acta Med Scand 183: 323–327PubMedCrossRefGoogle Scholar
  20. 20.
    Dustan HP, Tarazi RC, Bravo EL (1972) Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med 286: 861–866PubMedCrossRefGoogle Scholar
  21. 21.
    Cody RJ Jr, Tarazi RC, Bravo EL, Fouad FM (1978) Hemodynamics of orally active converting enzyme inhibitor (SQ 14,225) in hypertensive patients. Clin Sci Mol Med 55: 453–459PubMedGoogle Scholar
  22. 22.
    Bravo EL, Tarazi RC, Fouad FM (1980) Hemodynamic effects of long-term captopril therapy in hypertensive man. In: Proceedings of the Physiological Society of Philadelphia (In press )Google Scholar
  23. 23.
    Ferrone JA, Kardon MB, Walsh GM (1978) Systemic hemodynamic effects of converting enzyme inhibitor (CEI, SQ 14,225) during acute renovascular hypertension. Fed Proc 37: 718 (Abst)Google Scholar
  24. 24.
    Murthy VS, Wldron TL, Goldberg ME (1978) Inhibition of angiotensin converting enzyme by SQ 14,225 in anesthetized dogs: Hemodynamic and renal vascular effects. Proc Soc Exp Biol Med 157: 121–124PubMedGoogle Scholar
  25. 25.
    Tarazi RC (1978) Antihypertensive effect of beta-blockade: Relation of its hemodynamic component to other mechanisms. In: Braunwald E (ed) Beta-adrenergic blockade. A new era in cardiovascular medicine. Excerpta Medica/Elsevier, New York, pp 210–224Google Scholar
  26. 26.
    Tarazi RC (1976) Hemodynamic role of extracellular fluid in hypertension. Circ Res 38 (Suppl II): 72–83Google Scholar
  27. 27.
    Fiorentini R, Fouad FM, Bravo EL, Tarazi RC (1980) Combined adrenoreceptor and angiotensin blockade in resistant hypertension. Clin Pharmacol Ther 27 (2): 253 (Abst)Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1981

Authors and Affiliations

  • Robert C. Tarazi
  • Emmanuel L. Bravo
  • Fetnat M. Fouad

There are no affiliations available

Personalised recommendations